Trial Pits Upadacitinib vs. Adalimumab for Psoriatic Arthritis
The Rheumatologist reports on clinical study results published in The New England Journal of Medicine finding a 30 mg dose of upadacitinib was superior to adalimumab—and a 15 mg dose of upadacitinib was non-inferior to adalimumab as treatments for psoriatic arthritis (PSA), and includes commentary on the results from Vivian P. Bykerk, BSc, MD, FRCPC, rheumatologist at HSS.
Dr. Bykerk said the results are encouraging but also noted the 30 mg dose of upadacitinib was associated with more safety concerns and severe adverse advents. She explained, “If this dose is approved for use in patients with PsA, providers will need to use it with caution.”
She added, “Upadacitinib 15 mg daily is a very good option for treatment of PsA, with a safety profile consistent with Janus kinase (JAK) inhibitors in other trials. If physicians choose JAKs for PsA, they should continue to monitor lab results for changes.”
Read the full article at The-rheumatologist.org.